PSMA PET Imaging and Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Acinar Adenocarcinoma & Ductual Adenocarcinoma), By Application (Hospitals, Diagnostic Centers & Academic Research Institutions), and Regional Forecast From 2026 To 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

PSMA PET IMAGING AND TREATMENT MARKET OVERVIEW

The global PSMA PET Imaging and Treatment Market is estimated to be valued at approximately USD 1.25 Billion in 2026. The market is projected to reach USD 14.25 Billion by 2035, expanding at a CAGR of 33.47% from 2026 to 2035.North America dominates with ~45% share due to advanced oncology infrastructure, followed by Europe at ~30% and Asia-Pacific at ~20%. Growth is driven by rising prostate cancer diagnostics and precision medicine.

The PSMA PET Imaging and Treatment Market centers on using techniques that focus on Prostate-Specific Membrane Antigen (PSMA), generally used to detect and treat prostate cancer. Using PSMA PET, healthcare providers can clearly view cancer cells and carry out early treatment planning. It is developing fast thanks to more cases of prostate cancer and improvements in radiology and imaging technology. These therapies are believed to work by directing radiation precisely to cancer cells while leaving other healthy body tissue intact. Generally, the market is likely to grow a lot as more people innovate and adopt this field globally.

KEY FINDINGS

• Market Size and Growth: Global PSMA PET Imaging and Treatment Market size is valued at USD 1.25 billion in 2026, expected to reach USD 14.25 billion by 2035, with a CAGR of 33.47% from 2026 to 2035.
• Key Market Driver: Rising prostate cancer prevalence supports demand, with 58% advanced cases adopting targeted imaging and 63% oncologists preferring PSMA-based diagnostics.
• Major Market Restraint: High procedural costs limit access, as 41% healthcare facilities report reimbursement challenges and 36% patients face affordability constraints.
• Emerging Trends: Theranostics expansion accelerates, with 52% centers integrating radioligand therapy and 47% clinical trials focusing on precision oncology solutions.
• Regional Leadership: North America leads with 45% share, followed by Europe at 30% and Asia Pacific accounting for 20% market presence.
• Competitive Landscape: Market moderately concentrated, with top 5 companies holding 49% share while 51% remains distributed among specialized radiopharmaceutical providers.
• Market Segmentation: Acinar Adenocarcinoma dominates with 61%, Ductal Adenocarcinoma accounts for 24%, and Others contribute 15% share.
• Recent Development: Clinical adoption increased by 45%, while 54% research institutions expanded PSMA-targeted therapy programs to enhance treatment precision outcomes.

GLOBAL CRISES IMPACTING PSMA PET IMAGING AND TREATMENT MARKET

PSMA PET Imaging and Treatment Industry Had a Negative Effect Due to Pandemic disruption during COVID-19

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The pandemic caused the PSMA PET Imaging and Treatment Market to fall sharply when worldwide lockdowns and disruptions in healthcare reached their peak. Most elective and routine imaging tests were pushed back or stopped during the pandemic, which caused PSMA PET scan demand to fall. The lack of supplies in the chain slowed the delivery of radiotracers and much-needed devices, further reducing market earnings. When patients avoided going to healthcare sites, this delayed getting treatment and worsened the outcomes of some clinical cases. On the whole, these combined problems stopped the market from advancing and being adopted during the pandemic.

LATEST TRENDS

AI drives market growth in PSMA PET imaging and treatment

There is an increasing improvement in the market for PSMA PET imaging and treatment, mainly thanks to AI helping with diagnoses and treatment design. Nowadays, AI algorithms are commonly used to look at PSMA PET images to find prostate cancer and measure how the cancer reacts to therapy. They are designed to aid clinicians in looking at medical images, which helps them treat each patient more personally. Mathematical models help us check many lesions, watch how tumors advance, and evaluate how well the treatment is working. This means AI is allowing doctors to use imaging more accurately and with greater efficiency for handling prostate cancer.

• According to the U.S. Food and Drug Administration (FDA), prostate cancer accounts for nearly 27% of all new cancer cases among men in the United States, driving accelerated approvals of PSMA-targeted PET imaging agents to improve diagnostic precision.

• According to the International Atomic Energy Agency (IAEA), nuclear medicine procedures have increased by approximately 20% over the past decade globally, reflecting expanded clinical adoption of targeted radioligand therapies such as PSMA-based treatments.

•   
•   
  

  Download Free Sample to learn more about this report

    

PSMA PET IMAGING AND TREATMENT MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Acinar Adenocarcinoma & Ductual Adenocarcinoma

• Acinar Adenocarcinoma: Acinar adenocarcinoma is usually seen, as it is made up of glands that look similar to those found in normal prostate tissue. Because acinar adenocarcinoma expresses PSMA strongly, PSMA PET imaging accurately determines the tumor site. Using PSMA-targeted therapies in this subtype results in better diagnoses and outlook during treatment. As a result, the use of PSMA PET imaging and treatment is extensive for patients with acinar adenocarcinoma.

• Ductal Adenocarcinoma: While most prostate cancers do not, ductal adenocarcinoma develops from the ducts within the prostate gland and is considered both rare and difficult to treat. Because these tumors often stand out differently from standard cancers, PSMA PET helps by clearly identifying them, which may be difficult with usual imaging methods. Due to ductal adenocarcinoma’s aggressive form, special PSMA-targeted methods are needed to improve a patient’s prognosis. Awareness has encouraged the use of specialized tests and treatments that are fitted to adults with this type.

By Application

Based on Application, the global market can be categorized into Hospitals, Diagnostic Centers & Academic Research Institutions

• Hospitals: Doctors in hospitals rely on PSMA PET imaging and treatment to detect and manage all stages of prostate cancer. They combine these advanced instruments in different oncology training programs to better support patients. PSMA PET helps hospitals improve their accuracy in staging and following patients’ response to therapy, which supports better clinical results. Hospitals see increasing demand because prostate cancer treatments must be both precise and individualized.

• Diagnostic Centers: Providing safe and reliable scans is the reason diagnostic centers are central to the success of the PSMA PET market. These approaches help locate prostate cancer in the body as early as possible, thanks to high-quality PSMA PET imaging. Centers of this kind frequently work with hospitals and clinics to ensure quick and accurate diagnosis and treatment. Market growth is largely driven by these companies increasing PSMA imaging for more people.

• Academic research institutions : Leading research centers encourage both new ideas and proof of the effectiveness of PSMA PET imaging and therapy. They organize and carry out studies and clinical trials looking for new radiotracers and therapeutic methods. Thanks to them, protocols for performing imaging have improved, and experts know more about how prostate cancer works. They support market progress by introducing PSMA-based solutions for the future.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.                          

DRIVING FACTOR

Rising prostate cancer cases drive market growth globally

Prostate cancer being detected more often globally is a major cause of growth in the PSMA PET Imaging and Treatment Market. When more patients are diagnosed, people require even more sensitive and specific diagnostic tools such as PSMA PET scans. Thanks to these scans, doctors can identify the disease early and properly stage it for better treatment choices. As a result, an increase in cases helps to drive the use and development of PSMA-based approaches.

• According to the World Health Organization (WHO), prostate cancer represents approximately 14% of all male cancers worldwide, strengthening demand for advanced imaging modalities like PSMA PET scans for early detection and staging.

• According to the European Association of Urology (EAU), PSMA PET imaging demonstrates detection rates exceeding 85% in patients with biochemical recurrence at higher PSA levels, significantly outperforming conventional imaging techniques.

Radiotracer advancements enhance accuracy, driving market growth

Radiotracer advances have made the PSMA PET market better by boosting both diagnostic and therapeutic results. Radiotracers in medicine today allow doctors to direct treatments to the right cells and track them more accurately. Because of this progress, it is possible to decrease the chance of damaging healthy tissue during treatment. Consequently, better radiotracers are making PSMA PET imaging and treatment more popular and resulting PSMA PET market  growth.

RESTRAINING FACTOR

High costs and limited access hinder market growth

The high expenses connected to PSMA PET imaging and treatment are playing a major role in slowing down this market’s growth. Because of the costly equipment, radiotracers, and specialized buildings needed, only a few people in low- and middle-income regions can access nuclear medicine. Not to mention, it is sometimes hard for patients to obtain care because of problems with insurance and reimbursement. Because these expenses are high, PSMA PET imaging and therapies are not accessible to everyone, and market progress is slowed.

• According to the International Atomic Energy Agency (IAEA), over 50% of low- and middle-income countries lack adequate nuclear medicine facilities, restricting widespread access to PSMA PET imaging services.
• According to the U.S. Nuclear Regulatory Commission (NRC), compliance and radiation safety standards apply to 100% of licensed radiopharmaceutical production sites, increasing operational complexity and costs for manufacturers.

Personalized medicine and global outreach drive market growth

Opportunity

There is a new chance to grow in the PSMA PET Imaging and Treatment Market thanks to personalized medicine and specialized treatments. Raising funds for new research into PSMA-based compounds and how to use them with other therapies can improve both treatment results and patients’ outcomes. Besides, greater understanding of breast cancer and the launch of screening programs in less developed countries create new possibilities for businesses. As a result, there is a bigger opportunity for reaching more markets globally.

• According to the World Nuclear Association, more than 10 million nuclear medicine procedures are conducted annually worldwide, creating significant opportunity for integrated PSMA imaging and therapeutic solutions.

• According to the United Nations Department of Economic and Social Affairs (UN DESA), the population aged 65 years and above is projected to account for nearly 16% of the global population by 2050, increasing prostate cancer screening and diagnostic imaging demand.

Regulatory hurdles slow innovation, limiting market growth worldwide

Challenge

The PSMA PET Imaging and Treatment Market encounters a major challenge from the requirement to receive lengthy and difficult regulatory permission. Tough requirements for new radiotracers and therapies make it harder for them to reach patients early. Also, because every nation’s regulations are not the same, companies find it harder to expand globally. As a result, the use of PSMA-based techniques comes late and lacks consistent advancement. This challenge also limits clinical trial diversity and delays innovation, as developers must navigate complex approval landscapes in multiple regions. Smaller biotech firms, in particular, face significant resource constraints, making it even more difficult to bring new PSMA imaging and treatment solutions to market swiftly and efficiently.

• According to the Organisation for Economic Co-operation and Development (OECD), public health expenditure accounts for approximately 76% of total health spending across member countries, meaning reimbursement policy decisions significantly influence adoption of advanced imaging technologies.

• According to the Nuclear Energy Agency (NEA), nearly 60% of global medical radioisotope production relies on a limited number of aging nuclear reactors, posing supply risks for PSMA-based diagnostic and therapeutic agents.

•   
•   
  Download Free Sample to learn more about this report

    

PSMA PET IMAGING AND TREATMENT MARKET REGIONAL INSIGHTS

• North America

Strong healthcare and innovation fuel North America's market growth

From 2026 to 2035, North America is projected to command approximately 45% of the global PSMA PET imaging and treatment market, driven by advanced healthcare infrastructure and widespread adoption of precision diagnostic technologies.The main reason North America is in charge of the PET Imaging and Treatment Market for Prostate Cancer is its top-class health services, high number of prostate cancer cases, and commitment to research. Many U.S. healthcare facilities use the latest imaging technology, and reliable compensation policies have been set up in the field. Significant growth in the United States PSMA PET Imaging and Treatment Market is influenced by large funding and groundbreaking innovation from the United States. Since there are many patients in the country and a lot of active clinical trials, the market continues to grow rapidly.

• Europe

Europe’s innovation, healthcare, and support drive market growth

Over 2026–2035, Europe is anticipated to hold nearly 30% of the global PSMA PET imaging and treatment market, bolstered by strong clinical research activities and enhanced reimbursement frameworks.The PSMA PET Imaging and Treatment Market is helped by research and development in nuclear medicine and oncology that are key aspects in Europe. Because the region has modern healthcare systems, people can receive advanced diagnostics and targeted treatment methods. More people in Europe are turning to PSMA PET imaging because of programs that aim to improve early detection. Joining efforts between European universities and companies propels growth in innovation and the market throughout the continent. Additionally, government support for cancer research, favorable reimbursement policies, and increased clinical trial activity further strengthen the market.

• Asia

During the forecast period of 2026–2035, the Asia Pacific region is expected to capture around 20% share of the PSMA PET imaging and treatment market, supported by rising cancer incidence and expanding healthcare investments.Asia holds remarkable PSMA PET Imaging and Treatment Market share because the patient population with prostate cancer is rising. Investments in healthcare and better hospitals are allowing more people in the area to use advanced imaging technology. Besides, showing people the importance of screening tests is raising the need for early treatment-focused therapies. Asia’s market for cancer medicines is growing quickly thanks to fast economic growth and government measures to improve cancer care. Moreover, partnerships between local healthcare providers and global pharmaceutical companies are fostering the introduction of cutting-edge PSMA radiotracers and therapies

KEY INDUSTRY PLAYERS

Major players’ innovations, partnerships, and expansions drive market growth

Significant changes in the PSMA PET Imaging and Treatment Market are being driven by major players through advancements, growing their products, and teaming up with other companies. Advanced PSMA-focused radiotracers and better methods for imaging have been developed using heavy investments in research and development by leading companies. They partner with healthcare professionals and academic organizations to speed up both clinical trials and the process of getting regulatory approval. By offering solutions everywhere and expanding what they offer, these players make it simpler for more people to access the market. When they use mergers and acquisitions, they increase their influence in the market and help boost the PET imaging and treatment industry.

• Novartis: According to corporate reports, Novartis operates in over 140 countries and invests approximately 20% of net sales into research and development, including radioligand therapy platforms targeting PSMA.

• Clarity Pharmaceuticals: According to company information, Clarity’s radiopharmaceutical programs utilize copper isotopes with half-lives exceeding 12 hours, enabling extended diagnostic imaging windows.

List of Top PSMA Pet Imaging And Treatment Companies

• Telix (Australia)
• Novartis (Switzerland)
• Clarity (Australia)
• RadioMedix (U.S)
• Lantheus (U.S)

KEY INDUSTRY DEVELOPMENT

May 2023: Recently, Blue Earth Diagnostics was given U.S. Food and Drug Administration (FDA) approval for Posluma (flotufolastat F-18), a new PSMA-targeted PET imaging agent. Posluma is suitable for diagnosing PSMA-positive lesions in men with prostate cancer whose PSA levels may suggest hidden cancer or previous recurrences. Getting this approval means Posluma is the first and only radiohybrid agent created for imaging prostate cancer and approved by the FDA.

REPORT COVERAGE      

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential Applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.